Protalix BioTherapeutics Rating Lowered to Hold at Canaccord Genuity (PLX)

By admin | 7 years ago

Protalix BioTherapeutics (NYSE: PLX) was downgraded by investment analysts at Canaccord Genuity from a “buy” rating to a “hold” rating in a note issued to investors on Wednesday. They currently have a $8.00 target price on the stock.

Shares of Protalix BioTherapeutics traded down 2.85% during mid-day trading on Wednesday, hitting $6.81. Protalix BioTherapeutics has a one year low of $4.06 and a one year high of $7.70. The company’s market cap is $618.5 million.

Separately, analysts at Auriga downgraded shares of Protalix BioTherapeutics from a “buy” rating to a “hold” rating in a research note to investors on Monday. They now have a $8.00 price target on the stock.

Protalix BioTherapeutics, Inc. is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on the ProCellEx protein expression system (ProCellEx).

About the author